From mAb to bsAb – Accelerating bispecific antibody design and production for targeted cancer therapeutics.
Case study summary
A cancer therapeutics company partnered with evitria to reformat a tumor-targeting monoclonal antibody into a TAA x CD3 bispecific for proof-of-concept studies. evitria designed and produced six bispecific variants with different formats, valencies, and Fc-engineering features.
All constructs were delivered within 4.5 weeks and showed comparable target-binding affinity and thermal stability to the parental antibody. This case highlights evitria’s capability to rapidly engineer and optimize bispecific antibodies, supporting the client’s transition to in vivo studies.
Get the full case study by signing up through our form.
